Literature DB >> 10762527

PCV salvage chemotherapy for recurrent primary CNS lymphoma.

U Herrlinger1, W Brugger, M Bamberg, W Küker, J Dichgans, M Weller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10762527     DOI： 10.1212/wnl.54.8.1707

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  26 in total

1.  Relapse of primary CNS lymphoma after more than 10 years in complete remission.

Authors:  Ulrich Herrlinger; Holger Hebart; Lothar Kanz; Johannes Dichgans; Michael Weller
Journal:  J Neurol       Date:  2005-05-20       Impact factor: 4.849

Review 2.  Diagnosis and treatment of primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

Review 3.  Biology and treatment of primary central nervous system lymphoma.

Authors:  Alain P Algazi; Cigall Kadoch; James L Rubenstein
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 4.  Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?

Authors:  Jerome J Graber; Antonio Omuro
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

Review 5.  Introduction of novel agents in the treatment of primary CNS lymphoma.

Authors:  Christian Grommes; Lakshmi Nayak; Han W Tun; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

6.  Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2014-03-01       Impact factor: 4.130

7.  Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response.

Authors:  Keith A Lerro; Jill Lacy
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

Review 8.  Primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 9.  Treatment of primary central nervous system lymphoma.

Authors:  Meltem Ekenel; Lisa M DeAngelis
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

10.  Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.

Authors:  Alfredo D Voloschin; Rebecca Betensky; Patrick Y Wen; Fred Hochberg; Tracy Batchelor
Journal:  J Neurooncol       Date:  2007-09-21       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.